Results 251 to 260 of about 14,082,843 (400)

Phosphorylation or Glutamic Acid Substitution at Protein Kinase C Sites on Cardiac Troponin I Differentially Depress Myofilament Tension and Shortening Velocity [PDF]

, 2003
Eileen M. Burkart, Marius P. Sumandea, Tomoyoshi Kobayashi, Mahta Nili, Anne F. Martin, Earl Homsher, R. John Solaro   +6 more
openalex   +1 more source

Serial high-sensitivity cardiac troponin I trajectories predict cardiovascular events in hemodialysis patients. [PDF]

Clin Kidney J
Wu Y, Li F, Fu Q, Wang Y, Wang J, Chen X, Wu T, Chen Q, Zhang N, Zhu D, Wang X.   +10 more
europepmc   +1 more source

Risk factors for silent cerebral infarction in immune‐mediated thrombotic thrombocytopenic survivors

British Journal of Haematology, EarlyView.
Summary Immune‐mediated thrombotic thrombocytopenic purpura (iTTP) survivors are predisposed to silent cerebral infarctions (SCI) defined as radiological evidence of brain ischaemia without focal symptoms. This study examined risk factors associated with SCI burden in iTTP survivors during remission.
Binish Javed, Jia Yu, Jenna Brown, Jay Meade, Gloria F. Gerber, Michael B. Streiff, Peggy Kraus, Samuel Merrill, Allyson M. Pishko, Jennifer Yui, Rakhi P. Naik, Robert A. Brodsky, Doris D. Lin, Shruti Chaturvedi   +13 more
wiley   +1 more source

Clinical Significance of Cardiac Troponin I Elevation in Detecting Immune Checkpoint Inhibitor-Induced Myocarditis. [PDF]

Circ Rep
Oikawa M, Haga F, Tani T, Yokokawa T, Miura S, Misaka T, Kaneshiro T, Yoshihisa A, Ishida T, Takeishi Y.   +9 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Cardiac-specific troponin-I (cTnI) in a post-mortem setting. [PDF]

Int J Legal Med
Sutton ED, Parsons S, Pricone M, de Boer HH.   +3 more
europepmc   +1 more source

Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes.

New England Journal of Medicine, 1996
E. Antman, M. Tanasijevic, B. Thompson, M. Schactman, C. Mccabe, C. Cannon, G. A. Fischer, A. Fung, C. Thompson, D. Wybenga, E. Braunwald   +10 more
semanticscholar   +1 more source

Correlation High-Sensitivity Troponin-I and Length of Stay Acute Myocardial Infarction Patients Dr. Wahidin Sudirohusodo Hospital

Nuran Sarı, Sulina Yanti Wibawa, Amaliyah T. Lopa   +2 more
openalex   +2 more sources

The Comparison and Validity of Troponin I Assay Systems in Diagnosing Myocardial Ischemic Injury After Surgical Coronary Revascularization [PDF]

, 2005
C. Bruce Martin, Andrew Shaw, János Gál, Natarajan Aravindan, Frank L. Murphy, David Royston, Bernhard Riedel   +6 more
openalex   +1 more source

A quad‐cistronic fluorescent biosensor system for real‐time detection of subcellular Ca2+ signals

British Journal of Pharmacology, EarlyView.
Background and Purpose The calcium ion (Ca2+) is a versatile cellular messenger regulating a variety of biological processes. Compounds modulating subcellular Ca2+ signals hold substantial pharmacological potential. Advances in fluorescent biosensors have revolutionised Ca2+ imaging.
Anna Lischnig, Yusuf C. Erdoğan, Benjamin Gottschalk, Michael Gruber, Andrea Groselj‐Strele, Sandra Burgstaller, Wolfgang F. Graier, Roland Malli   +7 more
wiley   +1 more source